To investigate the effect of distant metastases sites on survival in patients with de novo stage-IV breast cancer. From 2010 to 2013, patients with a diagnosis of de novo stage-IV breast cancer were identified using the Surveillance, Epidemiology, and End Results database. Univariate and multivariate Cox regression analyses were performed to analyze the effect of distant metastases sites on breast cancer-specific survival and overall survival. A total of 7575 patients were identified. The most common metastatic sites were bone, followed by lung, liver, and brain. Patients with hormone receptor+/ human epidermal growth factor receptor 2− and hormone receptor+/human epidermal growth factor receptor 2+ status were more prone to bone metastases. Lung and brain metastases were common in hormone receptor−/human epidermal growth factor receptor 2+ and hormone receptor−/human epidermal growth factor receptor 2− subtypes, and patients with hormone receptor+/ human epidermal growth factor receptor 2+ and hormone receptor−/human epidermal growth factor receptor 2+ subtypes were more prone to liver metastases. Patients with liver and brain metastases had unfavorable prognosis for breast cancer-specific survival and overall survival, whereas bone and lung metastases had no effect on patient survival in multivariate analyses. The hormone receptor−/human epidermal growth factor receptor 2− subtype conferred a significantly poorer outcome in terms of breast cancer-specific survival and overall survival. hormone receptor+/human epidermal growth factor receptor 2+ disease was associated with the best prognosis in terms of breast cancer-specific survival and overall survival. Patients with liver and brain metastases were more likely to experience poor prognosis for breast cancer-specific survival and overall survival by various breast cancer subtypes. Distant metastases sites have differential impact on clinical outcomes in stage-IV breast cancer. Followup screening for brain and liver metastases might be effective in improving breast cancer-specific survival and overall survival.
Introduction
Breast cancer is the most common malignancy in women, with approximately 1.7 million new cases of breast cancer occurring worldwide each year. 1 The incidence of breast cancer has increased dramatically over the past three decades, but with progress in early diagnosis and comprehensive treatment, breast cancer mortality has gradually declined in recent years. 2 With developments in imaging quality, the early detection of breast cancer has gradually increased but approximately 2.4%-6% of patients are still being diagnosed as de novo stage-IV breast cancer at the time of initial diagnosis. [3] [4] [5] The survival of de novo metastatic disease has improved with more prevalent use of novel oncology drug treatments such as endocrine therapy and monoclonal antibodies. [6] [7] [8] Retrospective studies have also shown that local treatment, including surgery and radiotherapy, can improve survival in stage-IV breast cancer patients. [9] [10] [11] [12] [13] In patients diagnosed with advanced breast cancer during follow-up, the most common metastatic sites were bone, followed by lung, liver, and brain. Furthermore, the survival of patients with various metastatic sites is variable. Patients with bone and lung metastases have better survival, while those with liver and brain metastases tend to have the poorest survival. 14, 15 The pattern of site-specific metastases is similar in patients with de novo stage-IV breast cancer. 16, 17 However, due to the limited number of patients and differences in treatment strategies, the effect of distant metastases sites on survival in patients with de novo stage-IV breast cancer remains controversial. [18] [19] [20] Breast cancer subtype (BCS) is based on the status of hormone receptor (HR), human epidermal growth factor receptor 2 (HER2), and Ki-67 and is an important factor in how breast cancer is treated. In this study, we investigated whether survival of de novo stage-IV breast cancer patients was affected by distant metastases sites and whether this effect was influenced by BCS in the systemic therapy era.
Materials and methods

Patients
From 2010 to 2013, patients diagnosed with stage-IV breast cancer at initial diagnosis were identified using the Surveillance, Epidemiology, and End Results (SEER) database. 21 Patients with the following inclusion criteria were included in the analysis: (1) breast cancer as the primary cancer diagnosis; (2) distant metastasis sites including bone, lung, liver, and brain metastases; and (3) the status of estrogen receptor (ER), progesterone receptor (PR), and HER2 being available. Informed consent is not required for SEER database data. This study was approved by the Ethics Committee of Xiamen Cancer Hospital, the First Affiliated Hospital of Xiamen University, and Sun Yat-sen University Cancer Center (Approval No. 2016J01635).
Clinicopathological features
The following demographic and clinicopathological factors were assessed: year of diagnosis, age, race, tumor size, nodal stage, tumor grade, local surgery, HR status, HER2 status, and marital status. From 2010, distant metastasis sites recorded in SEER included bone, lung, liver, and brain metastases. The subtypes of BCS were defined as HR+/ HER2−, HR+/HER2+, HR−/HER2+ and HR−/HER2−. The primary endpoints of this study were breast cancerspecific survival (BCSS) and overall survival (OS).
Statistical analysis
Statistical analyses were performed using SPSS software, version 18.0 (SPSS, Chicago, IL, USA). The χ 2 tests and Fisher's exact probability tests were used to analyze the differences between the qualitative data. Survival curves depending on the period of diagnosis were calculated according to the Kaplan-Meier method. The log-rank test was used to assess significant differences for BCSS and OS. Significant and independent risk factors for BCSS and OS were identified by Cox proportional hazard models. A p value <0.05 was considered to be statistically significant in all analyses.
Results
Patient demographics and clinicopathological characteristics
A total of 7575 patients were identified, and the median age was 60 years (range = 19-103 years). The demographics and clinicopathological characteristics of patients are shown in Table 1 . The number of patients diagnosed with stage-IV breast cancer increased gradually from 2010 to 2013. In this cohort, 75.5% of patients were ethnically White and 70.1% of patients were node positive. A total of 2449 (32.3%) patients received local surgery. There were 4622 (61.0%) patients with HR+/HER2− disease, 1273 (16.8%) with HR+/HER2+ disease, 663 (8.8%) with HR−/ HER2+ disease, and 1017 (13.4%) had the HR−/HER2− subtype. A total of 1384 (29.9%), 429 (33.7%), 230 (34.7%), and 406 (39.9%) patients with HR+/HER2−, HR+/HER2+, HR−/HER2+, and HR−/HER2− subtypes received local surgery, respectively.
Distribution of distant metastases sites
The distributions of distant metastases sites are shown in Table 2 . The most common metastatic sites were bone, followed by lung, liver, and brain. A total of 4843 (63.9%), 2004 (26.5%), 623 (8.2%), and 105 (1.4%) patients had one, two, three, and four metastatic sites, respectively. In patients with single metastatic site, a total of 1215 (37.2%), 364 (44.3%), 287 (43.9%), and 36 (34.3%) patients with bone, lung, liver, and brain metastases received local surgery, respectively. There were 449 (22.4%), 91 (14.6%), and 7 (6.7%) patients with two, three, and four metastatic sites received local surgery, respectively.
Patients with HR+/HER2− and HR+/HER2+ disease were more prone to bone metastases. Lung and brain metastases were common in HR−/HER2+ and HR−/HER2− subtypes, and patients with HR+/HER2+ and HR−/HER2+ subtypes were more prone to liver metastases ( Table 3 ).
Effect of distant metastases sites on survival
In the univariate analyses (Table S1) , patients with boneonly metastases were associated with longer BCSS and OS, whereas lung, liver, and brain metastases at diagnosis of metastatic disease were associated with a poorer BCSS and OS. Patients with HR+/HER2+ disease had the best BCSS and OS by univariate analyses.
In the multivariate Cox analyses, patients with liver (BCSS, hazard ratio (HaR) = 1.57, 95% confidence interval (CI) = 1.42-1.74, p < 0.001; OS, HaR = 1.535, 95% CI = 1.40-1.69, p < 0.001) and brain metastases (BCSS, HaR = 1.74, 95% CI = 1.515-2.00, p < 0.001; OS, HaR = 1.73, 95% CI = 1.53-1.98, p < 0.001) were significantly more likely to have an unfavorable prognosis for BCSS and OS, whereas patients with bone-only and lung metastases did not experience poor survival prognosis (Table 4 ).
Regression analysis was conducted to evaluate the prognostic value of BCS (the HR+/HER2− subtype was used as a reference; Table 4 ). The HR−/HER2− subtype was associated with a significantly poorer outcome in terms of BCSS and OS, HR+/HER2+ disease was associated with the best prognosis in terms of BCSS and OS, whereas there was no significant difference in survival between patients with HR+/HER2− and HR−/HER2+ disease ( Figure 2 ).
The effect of distant metastases sites on survival by various BCS was analyzed. In the univariate analyses, the sites of distant metastases had prognostic effect by various BCS, except in the HR−/HER2− subtype with lung metastases. Using multivariate analyses, liver and brain metastases were adverse prognostic factors for BCSS and OS in HR+/HER2−, HR+/HER2+, and HR−/HER2− subtypes. However, patients with bone-only and lung metastases experienced similar survival. In patients with the HR−/HER2+ subtype, lung, liver, and brain metastases were unfavorably associated with BCSS and OS, whereas bone-only metastasis was not associated with survival (Table S2 ). 
Discussion
In this study, we investigated the characteristics of distant metastasis of de novo stage-IV breast cancer and the effect of different metastatic sites on the survival of patients. Our study suggests that patients with different BCS have different metastatic patterns, while the site of distant metastasis is a prognostic factor for stage-IV breast cancer. Currently, the recommended definition for BCS refers primarily to ER, PR, HER2, and Ki-67 status. 22 Since the SEER database did not record patient Ki-67 status, we used ER, PR, and HER2 to establish the BCS. It has been found that BCS not only predicts the survival and treatment of patients, [23] [24] [25] but different BCS may also be associated with organ-specific metastases. In our previous study of patients who had developed metastatic breast cancer (MBC) during their follow-up, patients with HER2positive subtype (HR+/HER2+ and HR−/HER2+) experienced significant liver metastasis. Furthermore, those patients with luminal tumors (HR+/HER2− and HR+/HER2+) were more likely to be affected by bone metastasis, and patients with the HR−/HER2− subtype were more likely to experience lung and brain metastases. 26 Our results are similar to other studies. [27] [28] [29] [30] In this study, we found that patients with HR+/HER2− and HR+/HER2+ disease were more likely to have bone metastases, while distant metastatic stage was confirmed during the initial diagnosis of breast cancer. Furthermore, patients with HR−/HER2+ and HR−/HER2− disease were more likely to experience lung metastasis and brain metastasis, while liver metastases were common in those with HER2+ expression. These studies suggest that BCS may be characterized by typical patterns of metastatic spread, which supports the hypothesis that breast cancer is a systemic disease with heterogeneous characteristics.
Bone metastasis has been reported as the most common metastatic site of de novo stage-IV breast cancer, followed by lung, liver, and brain, 16, 17 which was similar to our study. Patients with stage-IV breast cancer represent a heterogeneous group whose prognosis and outcome may be dependent on the sites of distant metastases. Previous studies have found that brain and liver metastatic sites were found to be independent, unfavorable prognostic factors in patients who had developed MBC during their follow-up. 14, 15 However, the prognostic value of distant metastases sites in de novo stage-IV breast cancer remains controversial. In a study by Gerratana et al., 18 including 31% of patients with de novo disease, results showed that liver metastasis was an independent prognostic factor for OS, while bone-only, lung, and brain metastases had no effect on survival. However, due to the limited number of patients with brain metastases (n = 23), potential bias was introduced into that study. 18 Studies by Neuman et al. 19 found that bone metastases and visceral metastases were prognostic factors affecting survival, but not refined the patients with visceral metastases, which may have exerted potential impact on outcomes. In the study by Ording et al., there were 870 de novo patients (of 3518 patients), and patients with brainonly and liver-only metastases had an increased risk of mortality compared to patients who only had bone metastasis. Patients with lung-only metastasis experienced similar mortality rates as patients with bone-only metastasis. 20 In this study, we employed a population-based database to analyze the prognostic effect of distant metastases sites in de novo stage-IV breast cancer. Our results showed that bone-only and lung metastases in patients had no effect on BCSS and OS, whereas patients with liver and brain metastases experienced the highest rate of mortality. These studies suggest that distant metastases sites have a differential impact on clinical outcomes. These fundamental, cohortbased observations may assist physicians in evaluating the survival potential of patients with de novo stage-IV breast cancer. Although the SEER database did not document detailed treatment of patients, we enrolled patients after 2010; therefore, this study still conforms to the era of modern systematic therapy. In a contemporary treatment model, 5-year survival in HR-positive patients could reach 50%, 19 while the median OS of HER2-positive advanced breast cancer patients receiving trastuzumab-based therapy has exceeded 3 years. 31 Our study also found that survival in those with HR+/HER2+ disease was significantly better than survival in those with HR+/HER− and HR−/HER2+ disease, while those with HR−/HER2− disease had the poorest survival prospects. Our results are consistent with previous studies. 16, 32 Advances in chemotherapy, endocrine, and targeted therapy could result in improved survival in many patients with de novo stage-IV breast cancer.
In our study, bone metastases in different BCS did not affect survival, and lung metastasis was only of prognostic value in patients with the HR−/HER2+ subtype, whereas poor prognosis for liver metastases and brain metastases was unaffected by BCS. Bone metastases did not affect patient survival, which was associated with HR+/HER2− and HR+/HER2+ subtypes in the majority of patients with bone metastases. These patients may be able to better tolerate endocrine therapy and targeted therapy; in addition, radiotherapy and local surgery have also been shown to provide better control for bone and lung metastases. [33] [34] [35] Although, patients HER2+ subtype were more prone to liver metastases, which may benefit from combined HER2 targeted therapy. However, liver metastases may be regarded as a sign of systemic tumor spread, which is amenable to targeted therapy or systemic chemotherapy. 36 One reason for the poor survival of breast cancer patients with brain metastases may be the difficulty of drug entry into the blood-brain barrier. Therefore, it is necessary to re-evaluate stage-IV breast cancer patients according to the anatomic site of distant metastases and assess the criteria used to define the progression of disease.
It is important to describe some of the limitations in this study. First, retrospective studies are inherently biased. Second, the SEER database only included four specific sites of distant metastases at the initial diagnosis, and we could not obtain further details concerning the time of secondary metastasis. In addition, there was a lack of details concerning chemotherapy, endocrine therapy, targeted therapy, and specific treatment of metastatic organs in the SEER database.
In conclusion, our population-based study suggests that distant metastases sites have differential impact on clinical outcomes in de novo stage-IV breast cancer. We advocate follow-up screening during aftercare for brain and liver metastases, as this might be effective.
